Assessment of patients with leptomeningeal metastasis
Standardized Clinical Assessment of Patients With Leptomeningeal Metastasis
This study is trying to create a standard way to check how patients with leptomeningeal metastases are doing, so doctors can better understand and manage their condition.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Zurich Academic / other |
| Locations | 3 sites (Houston, Texas and 2 other locations) |
| Trial ID | NCT06417710 on ClinicalTrials.gov |
What this trial studies
This project aims to develop and validate a standardized scorecard for the neurological assessment of patients diagnosed with leptomeningeal metastases. The assessment will be utilized in both clinical trials and routine clinical practice to ensure consistent evaluation of patient conditions. By focusing on patients with confirmed or probable leptomeningeal disease, the study seeks to enhance the understanding and management of this complex condition. The study is observational and does not involve any interventional treatments.
Who should consider this trial
Good fit: Ideal candidates include adult patients with a confirmed diagnosis of extra-CNS primary solid cancer and leptomeningeal metastases.
Not a fit: Patients unable to provide informed consent or adhere to follow-up recommendations may not benefit from this study.
Why it matters
Potential benefit: If successful, this assessment tool could improve the accuracy of neurological evaluations and enhance treatment strategies for patients with leptomeningeal metastases.
How similar studies have performed: While this approach is focused on developing a standardized assessment tool, similar studies in neurological evaluations have shown promise in improving patient outcomes.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patients (18 years or more), female or male * Histologically confirmed diagnosis of extra-CNS primary solid cancer * Diagnosis of leptomeningeal metastases confirmed or probable per EANO ESMO criteria * Performance status compatible with enrolment into clinical trials * Ability to consent * Signed informed consent form from patient * Participation in a parallel clinical trial is allowed in this non-interventional study Exclusion Criteria: * Inability to give informed consent * Inability to adhere to recommended follow-up according to the treating physician Vulnerable participants will not be included.
Where this trial is running
Houston, Texas and 2 other locations
- MD Anderson Cancer Center — Houston, Texas, United States (Recruiting)
- Netherlands Cancer Institute — Amsterdam, Netherlands (Recruiting)
- University Hospital Zurich — Zurich, Switzerland (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.